產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人白血病抑制因子蛋白與其它公司提供的重組蛋白不同，rHuLIF蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人白血病抑制因子蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人白血病抑制因子蛋白
| Synonyms | Differentiation-stimulating Factor, D Factor, Melanoma-derived LPL Inhibitor, MLPLI |
| Species | Human |
| Accession | P15018 |
| GeneID | 3976 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人白血病抑制因子蛋白Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 180 amino acids. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK LGCQLLGKYK QIIAVLAQAF |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人白血病抑制因子蛋白Fully biologically active when compared to standard. The ED50 as determined by the dose-dependent proliferation of human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuLIF as determined by LAL method. |
| Reconstitution | 重組人白血病抑制因子蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-0.2 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人白血病抑制因子蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Eswari S, Sai Kumar G, Sharma GT. 2012. Zygote: 1-11. 2. Mathieu ME, Saucourt C, Mournetas V, et al. 2012. Stem Cell Rev, 8: 1-15. 3. Thomson AJ, Pierart H, Meek S, et al. 2012. Cell Reprogram, 14: 112-22. 4. Li HandGrumet M. 2007. Glia, 55: 24-35. |
| Background | Leukemia inhibitory factor (LIF) is a member of Interleukin 6 family. This protein is mainly expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF is used in mouse embryonic stem cell culture, because that removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. It is also used in phase II clinical trial, which can assist embryo implantation in women who have failed to become pregnant despite assisted reproductive technologies (ART). Mature human LIF (180 a.a.) shares 78 %, 82 %, 91 %, 88 % and 87 % a.a. sequence identity with mouse, rat, canine, bovine, and porcine LIF, respectively. |
